

Peru

Population 2016

32 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.6 (1.4–1.7)	4.9 (4.3–5.5)
Mortality (HIV+TB only)	0.46 (0.34–0.61)	1.5 (1.1–1.9)
Incidence (includes HIV+TB)	37 (28–47)	117 (90–148)
Incidence (HIV+TB only)	2.2 (1.6–2.8)	6.8 (5.2–8.7)
Incidence (MDR/RR-TB)**	3.5 (2.9–4.2)	11 (9.1–13)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	2.2 (1.7–2.8)	13 (9.9–17)	15 (12–19)
Males	2.5 (1.9–3.1)	19 (14–24)	22 (16–27)
Total	4.7 (3.5–5.9)	32 (24–41)	37 (28–47)

TB case notifications, 2016	
Total cases notified	31 079
Total new and relapse	29 733
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	84%
- % pulmonary	80%
- % bacteriologically confirmed among pulmonary	82%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.06 (0.04–0.07)

TB/HIV care in new and relapse TB patients, 2016		
	Number	(%)
Patients with known HIV-status who are HIV-positive	1 520	6%
- on antiretroviral therapy	1 044	69%

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			2 300 (2 200–2 400)
Estimated % of TB cases with MDR/RR-TB	6.3% (5.9–6.7)	24% (23–26)	
% notified tested for rifampicin resistance	76%	81%	25 144
MDR/RR-TB cases tested for resistance to second-line drugs			1 104
Laboratory-confirmed cases		MDR/RR-TB: 1 457, XDR-TB: 88	
Patients started on treatment ****		MDR/RR-TB: 1 645, XDR-TB: 88	

Treatment success rate and cohort size		
	Success	Cohort
New cases registered in 2015	87%	14 896
Previously treated cases registered in 2015	73%	2 273
HIV-positive TB cases registered in 2015	66%	1 124
MDR/RR-TB cases started on second-line treatment in 2014	34%	1 376
XDR-TB cases started on second-line treatment in 2014	65%	60

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	19%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	66% (61–73)

TB financing, 2017	
National TB budget (US\$ millions)	101
Funding source: 84% domestic, 9% international, 7% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



— New cases
— Previously treated cases
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically